Amylin Pharmaceuticals Inc  (AMLN) Trade Now »     Rate AMLN  -  Discuss AMLN  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

AMLN Analysis & Videos »


AMLN: Bull or Bear?

A Calendar of Expected Clinical Trial Results AMLN

73%

+7.75% in 304 days A Calendar of Expected Clinical Trial Results <> The accompanying table [click to enlarge] includes 58 entries of expected clinical trial results in addition to pending FDA applications for new product approvals + a list of companies which will be required to re-submit their applications due to complete response letters from the agency. See my recent article on 20 emerging healthcare stocks to watch in 2009 for more details on some of the companies included in the accompanying calendar, in addition to the following companies with near-term catalysts in... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  01/11/09

Comment

Updated FDA Calendar AMLN

73%

+15.03% in 29 days (closed on 01/11/09) Updated FDA Calendar: Buying Cypress Bioscience <> The accompanying table [click to enlarge] includes a weekly update of 71 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Decision Catalyst Index. Since my article last week , the following action has taken place at FDA: 1.) Pain Therapeutics (PTIE) & King Pharma (KG) lost 21% and 7%, respectively, today after receiving a complete response letter from the FDA for their abuse-resistant form of controlled-release oxycodone, which is designed to deter the abuse and diver... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  12/12/08

Comment

Amylin, Lilly: Another Case of a Panic Driven Sell-Off AMLN

-39.39% in 440 days On Tuesday August 26, Amylin (AMLN) and its partner Eli Lilly (LLY) announced that four patients had died while on diabetes treatment Byetta. Both Amylin (down 12%) and Lilly (down 1%) sold off in after hours following repeated headlines saying Byetta was responsible for the deaths. Continue reading »

By  A. Reza Saadat   (-30.94%  risk: conservative)  08/27/08

Comment

Amylin Pharmaceuticals (AMLN) Shares Gain Ground on Outlook for Byetta AMLN

34%

-5.22% in 3 days (closed on 08/28/08) I've been stating for a while now that this market has changed character - even as the bear market hit us in the winter we were still able to find pockets of strength where buying breakouts were rewarded. However, at this time instead of buying breakouts, the course of action appears to be (mostly) to buy the broken down stocks and wait for the rebound. Unfortunately you have to sell the rebound as well - since if it lasts too long it turns into a breakout. Which means it's doomed to fail. ;) There are exceptions of course - no rule is hard and fast in any market. But we've gone from a t... Continue reading »

By  Trader Mark   (-7.11%  risk: moderate)  08/25/08

Comment

Bookkeeping: Beginning Amylin Pharmaceuticals (AMLN) AMLN

34%

-13.82% in 5 days (closed on 08/25/08) I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals (AMLN). This is one of the few biotechs I know pretty well, and have followd for quite a while - mostly due to its diabetes drug Byetta. Which is the cause of the recent ruckus - on Monday the FDA warned that Byetta might be linked to 6 severe cases of pancreatitis. <><>U.S. health regulators warned of more cases of dangerous pancreas inflammation in patients taking Amylin Pharmaceuticals Inc's (AMLN) diabetes drug,... Continue reading »

By  Trader Mark   (-7.11%  risk: moderate)  08/20/08

Comment

Amylin Pharmaceuticals Inc. AMLN

62%

-52.53% in 506 days Amylin and Mallinckrodt amended their manufacturing agreement dated October 1, 2003, pursuant to which Mallinckrodt manufactures and supplies to Amylin bulk exenatide, the active ingredient in BYETTA injection. Under the terms of the Amendment, the termination date of agreement has been extended for a period of four years to September 30, 2012. Continue reading »

By  Marian Filo   (-24.55%  risk: aggressive)  06/22/08

Comment

Cash Burn a Problem for Amylin AMLN

+53.04% in 517 days Byetta will probably be a billion-dollar product in 2010 and the company will still will not be profitable. Continue reading »

By  Zacks.com   (-14.33%  risk: moderate)  06/11/08

Comment

Will Yahoo Settle? Fast Money Recap (5/28/08) AMLN

-60.69% in 530 days Recap of CNBC's Fast Money, Wednesday May 28. <!----> <> Oil Rebounds: AMR (AMR), UAL (UAUA), Alpah Natural Resources (ANR), Consol Energy (CNX), Massey (MEE), Eastman Chemical (EMN), Sasol (SSL), First Solar (FSLR), Energy Conversion Deviced (ENER) <>Macke said Nigerian rebels were a convenient excuse for oil to go higher, and that the upward trend will last. Guy Adami likes AMR and noted there is talk of a deal between UAL and U.S. Airways. Macke would sell the airline rally and Pete Najarian says oil will have to drop before airlines recover. Pete Najarian is bullish on natural gas and co... Continue reading »

By  SA Editor Miriam   (-20.07%  risk: moderate)  05/29/08

Comment

Bullish on AMLN ... AMLN

-61.34% in 587 days Continue reading »

By  Scott Rothbort   (-61.34%  risk: moderate)  04/02/08

Comment

People Bullish on AMLN

tired_ant Analyst N/A 28 days ago	Mike Havrilla Principal 73% 10 mos ago	flagman1 Analyst 73% about 1 year ago
richbull Associate 38% about 1 year ago	A. Reza Saadat Tracked Blogger N/A about 1 year ago

People Bearish on AMLN

3mmanu3l Analyst N/A about 1 mo ago	cdavidm43 Analyst 80% 8 mos ago	Zacks.com Tracked Blogger 28% about 1 year ago
caho Analyst  2 % over 2 years ago	kkp Analyst N/A over 2 years ago

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.